Ventyx’s stock soars on cardiovascular data for NLRP3 drugnews2025-10-23T14:31:10+00:00October 23rd, 2025|Endpoints News|
Are recent strides in neurology R&D enough to make it a hot M&A target?news2025-10-23T14:00:48+00:00October 23rd, 2025|Endpoints News|
Moderna’s CMV vaccine fails Phase 3 study, company to halt most developmentnews2025-10-22T20:05:30+00:00October 22nd, 2025|Endpoints News|
Alkermes to buy Avadel for up to $2.1Bnews2025-10-22T19:27:45+00:00October 22nd, 2025|Endpoints News|
Arcturus announces mixed results of mRNA cystic fibrosis therapy, Covid-19 vaccine delaynews2025-10-22T18:39:22+00:00October 22nd, 2025|Endpoints News|
Terns ditches obesity pill and pivots to cancer after mid-stage letdownnews2025-10-22T15:04:19+00:00October 22nd, 2025|Endpoints News|
Sanofi reveals Phase 2 rare disease win from Inhibrx buyoutnews2025-10-22T13:27:00+00:00October 22nd, 2025|Endpoints News|
Alector’s GSK-partnered dementia drug flunks Phase 3, plots to halve workforcenews2025-10-22T12:58:17+00:00October 22nd, 2025|Endpoints News|
GSK, Spero reveal full Phase 3 data for oral antibiotic, set for end-of-year filingnews2025-10-21T14:45:04+00:00October 21st, 2025|Endpoints News|
CRISPR Therapeutics says its new gene editing tool is ‘a significant advance’ over prime editing. Prime Medicine disagreesnews2025-10-21T11:00:14+00:00October 21st, 2025|Endpoints News|
